Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 7, 2021; 27(17): 2025-2038
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2025
Table 1 Comparison of the clinical characteristics of patients with and without hepatocellular carcinoma
Characteristic
no-HCC group (n = 145)
HCC group (n = 121)
P value
Age ≥ 60 yr, n (%)41 (28.3)64 (52.9)< 0.001
Male, n (%)99 (68.3)91 (75.2)0.133
Etiology of liver cirrhosis, n (%)
HBV101 (60.7)76 (62.8)0.363
HBV + alcohol31 (21.4)45 (37.2)0.006
HBV + HEV1 (0.6)0 (0.0)-
HBV + schistosome1 (0.6)0 (0.0)-
Smoking history, n (%)21 (14.5)51 (42.1)< 0.001
Family history of HBV-related HCC, n (%)10 (6.9)23 (19.0)0.004
Medication history
Duration of NA treatment, yr, median (P25, P75)3.9 (2.1, 5.8)5.4 (2.3, 6.9)0.067
LAM resistance, n (%)18 (12.4)27 (22.3)0.021
HBsAg level, IU/L, median (P25, P75)255.0 (56.0, 678.0)269.0 (67.0, 656.0)0.456
HBeAg positive, n (%)37 (25.5)21 (17.4)0.136
HBV DNA negative, n (%)67 (46.2)39 (32.2)0.033
ALB, U/L36.29 ± 7.9833.34 ± 6.620.002
ALT, U/L, median (P25, P75)27.00 (18.00, 37.00)32.00 (21.27, 62.00)0.006
AST, U/L, median (P25, P75)33.00 (23.00, 47.00)44.50 (31.65, 96.85)< 0.001
GGT, U/L, median (P25, P75)33.00 (20.00, 46.00)61.50 (32.75, 160.75)< 0.001
ALP, U/L, median (P25, P75)99.00 (73.00, 126.00)134.50 (92.00, 198.85)< 0.001
TB, μmol/L, median (P25, P75)20.41 (13.81, 44.60)24.46 (16.60, 42.80)0.192
FBS, mmol/L, median (P25, P75)5.17 ± 0.686.99 ± 1.310.025
Ascites, n (%)33 (20.0)43 (34.7)0.022
Child-Pugh class, n (%)
A81 (55.9)55 (45.5)0.001
B38 (26.2)26 (21.5)0.561
C26 (17.9)40 (33.1)0.002
AFP ≥ 20 μg/L, n (%)14 (9.7)56 (46.3)< 0.001
PT s, median (P25, P75)13.25 (11.80, 14.20)13.51 (12.41, 15.02)0.475